Merck’s Oxytrol Could Be OTC Trailblazer For Chronic Conditions
This article was originally published in The Tan Sheet
Executive Summary
Merck’s Oxytrol for Women has the opportunity to “create the market” for OTC overactive bladder drugs, as well as encourage other switches for chronic, progressive conditions, marketing consultant Joe McGovern says. The transdermal patch product is slated to launch in September.
You may also be interested in...
Perrigo Counts 32 Billion Reasons To Reject Mylan Offers
In addition to announcing it to turned down Mylan’s offer of $205 per share or roughly $28.9 billion, Perrigo reports a 41% increase in adjusted net income to a company-record $248.5 million in its latest quarter. The firm plans to launch a generic of Sanofi’s Nasacort 24 HR in time for the 2015 allergy season.
Perrigo Counts 32 Billion Reasons To Reject Mylan Offers
In addition to announcing it to turned down Mylan’s offer of $205 per share or roughly $28.9 billion, Perrigo reports a 41% increase in adjusted net income to a company-record $248.5 million in its latest quarter. The firm plans to launch a generic of Sanofi’s Nasacort 24 HR in time for the 2015 allergy season.
Michele To Lead FDA OTC Division Amid NSURE Uncertainty
Theresa Michele moves from CDER’s Division of Pulmonary, Allergy and Rheumatology Products to direct the Division of Nonprescription Clinical Evaluation.